Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06838429 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PARPi and Ovarian Cancer Survival

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 20, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
With the widespread use of PARP inhibitors (PARPi) as maintenance therapy in ovarian cancer, there is still a lack of real-world data from large samples regarding their impact on survival outcomes in advanced and recurrent ovarian cancer. This study aims to conduct a pragmatic cohort study to evaluate the impact of first-line and second-line maintenance treatment with PARPi on survival rates in patients with advanced and recurrent ovarian cancer. The genetic status, different PARPi drugs, and the use of anti-angiogenic inhibitor maintenance therapy or not is used as confounding factors.
Trial Details
NCT Number NCT06838429
Lead Sponsor Shanghai Gynecologic Oncology Group
Collaborators: Fudan University, Department of Gynecologic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China, Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University, Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China
Conditions
(from sponsor)		 Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, PARP Inhibitor
Related terms Carcinoma, Ovarian Epithelial
Enrollment 6,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov